MaxCyte (MXCT) Q4 2024: Core Revenue Growth of 20% Highlights Resilience Amid SPL Milestone Lull

March 11, 2025 | By EarningsIQ Research

MaxCyte demonstrated solid core business momentum with a 20% increase in core revenue despite a sharp decline in milestone-driven SPL program revenue. The strategic acquisition of SecureDx broadens MaxCyte’s platform reach, setting a foundation for diversified growth in 2025. Management’s cautious guidance reflects macro uncertainties but signals confidence in continued commercial execution and operational discipline.

Summary

• Core Business Resilience: Sustained growth in instruments, licenses, and processing assemblies reflects strong customer engagement.
• Strategic Platform Expansion: Acquisition of SecureDx enhances end-to-end cell and gene therapy support across viral and non-viral modalities.
• Conservative Outlook Amid Macro Uncertainty: Guidance anticipates 8% to 15% core revenue growth without assuming market recovery.

Business Overview

MaxCyte is a cell-engineering technology company that provides enabling platforms for the development of cell and gene therapies. The company generates revenue primarily through the sale and licensing of instruments, proprietary processing assemblies (PAs), and licenses under its Strategic Platform License (SPL) agreements. MaxCyte’s business model centers on a recurring revenue base from consumables and licenses, complemented by milestone and royalty payments from SPL program-related revenue tied to clinical progress of partners’ therapies.

Performance Analysis

In the fourth quarter of 2024, MaxCyte reported total revenue of $8.7 million, down 45% year-over-year, largely due to the absence of multiple one-time approval milestones recognized in Q4 2023. However, core business revenue, which excludes SPL program-related revenue, rose 20% to $8.6 million, highlighting underlying growth in the company’s recurring revenue streams. This growth was driven by a 93% increase in processing assembly sales and stable license revenue, partially offset by a 30% decline in instrument sales reflecting cautious capital spending by customers.

For the full year, total revenue declined 6% to $38.6 million, with core revenue increasing 9% to $32.5 million, underscoring the company’s ability to expand its installed base and consumable sales despite a challenging environment. The SPL program-related revenue, which includes milestone and royalty payments, decreased 47% to $6.1 million, reflecting timing variability in partner clinical progress. Gross margin contracted from 89% to 82%, with adjusted non-GAAP gross margin remaining robust at 84% excluding SPL revenue and inventory reserves.

• Installed Base Expansion: The instrument installed base grew to 760 units, up 11% year-over-year, supporting increased consumable pull-through.
• SPL Portfolio Growth: MaxCyte signed a record six new SPL agreements in 2024, growing to 28 active SPL customers with 18 clinical-stage programs.
• Operational Efficiency: Operating expenses declined 3% year-over-year due to strategic streamlining, aiding disciplined cash management.

While net loss widened to $10.6 million in Q4 and $41.1 million for the year, the company maintains a strong balance sheet with $190 million in cash and investments at year-end, enabling continued strategic investments and acquisitions.

Executive Commentary

Strategic Positioning

1. Diversification Through SecureDx Acquisition

The acquisition of SecureDx, a specialized safety assessment services platform for cell and gene therapy development, significantly broadens MaxCyte’s addressable market. SecureDx complements MaxCyte’s electroporation technology by offering off-target gene editing profiling applicable in both viral and non-viral modalities, across ex vivo and in vivo therapies. This integration positions MaxCyte as an end-to-end solutions provider, enhancing customer value and cross-selling opportunities.

2. SPL Program Expansion and Clinical Pipeline Growth

MaxCyte’s SPL portfolio expanded to 28 active agreements, including 18 clinical-stage programs and one commercial program. This represents a 50% increase in active clinical programs since the company’s IPO in 2021, outpacing the 25% market growth in non-viral cell therapies. The company highlights a $220 million pre-commercial milestone potential from these active clinical programs, signaling significant long-term revenue opportunity as programs advance toward pivotal trials and commercialization.

3. Recurring Revenue Growth and Installed Base Leverage

Core revenue growth is driven by expanding the installed base of instruments, which rose 11% to 760 units, and increased sales of processing assemblies, which grew 36% year-over-year. This recurring revenue model provides stability and visibility, as consumables and licenses represent the majority of core revenue, mitigating volatility from milestone-based SPL program revenue.

4. Operational Discipline and Cash Management

Despite revenue headwinds from SPL milestone timing, MaxCyte reduced operating expenses by 3% year-over-year through organizational streamlining and capital efficiency. The company ended 2024 with $190 million in cash and investments and expects to maintain a strong financial position with an anticipated year-end 2025 cash balance of approximately $160 million, supporting continued investments and business development.

5. Conservative Guidance Reflecting Macro Uncertainty

Management’s 2025 guidance anticipates 8% to 15% growth in core revenue, inclusive of SecureDx contributions, and approximately $5 million in SPL program-related revenue. This outlook does not assume improvement in the current macroeconomic environment but reflects confidence in the company’s commercial execution and pipeline progression. The guidance range incorporates potential variability in customer capital spending and clinical milestones.

Key Considerations

MaxCyte’s Q4 and full-year results reflect a business navigating a complex biotech funding environment while capitalizing on structural growth drivers.

• Milestone Revenue Volatility: The sharp decline in SPL program-related revenue underscores the lumpiness inherent in milestone-based income, requiring investors to focus on core revenue trends for stability.
• Recurring Revenue as Growth Anchor: Strong growth in processing assemblies and licenses demonstrates the value of MaxCyte’s consumable-driven model, which benefits from expanding clinical programs and instrument base.
• SecureDx Integration Synergies: Early-stage commercial traction combined with low incremental operating costs suggests SecureDx will enhance margins and diversify revenue streams over time.
• Customer Funding Environment: Management’s cautious tone on capital equipment sales reflects ongoing customer capital discipline, a critical factor for instrument revenue recovery.
• Pipeline Visibility: The growing number of clinical-stage SPL programs and increased milestone potential provide visibility into future revenue inflection points beyond 2025.

Risks

MaxCyte faces risks typical of a platform technology provider in a nascent and volatile cell and gene therapy market. Milestone revenue is inherently uncertain and dependent on partner clinical progress and regulatory approvals. Customer capital spending remains cautious amid macroeconomic uncertainties, potentially constraining instrument sales. Integration risks exist with SecureDx, although management reports smooth early integration. Competitive pressures in cell engineering platforms and evolving regulatory landscapes may also impact growth trajectories.

Forward Outlook

For 2025, MaxCyte guided to:

• Core revenue growth of 8% to 15%, inclusive of SecureDx contributions.
• SPL program-related revenue of approximately $5 million, reflecting milestone and royalty income.

Management emphasized that the guidance assumes a stable macroeconomic environment without factoring in potential market recovery or deterioration. They highlighted ongoing commercial execution, pipeline progression, and disciplined capital allocation as key drivers supporting this outlook.

Takeaways

MaxCyte’s 2024 results and 2025 guidance reveal a company balancing near-term revenue headwinds with long-term growth foundations.

• Core Revenue Strength: The 20% increase in core revenue in Q4 and 9% full-year growth demonstrate resilient demand for MaxCyte’s instruments, consumables, and licenses, underpinning a recurring revenue base that cushions milestone variability.
• Strategic Expansion Through SecureDx: The acquisition broadens MaxCyte’s technology footprint and customer reach, positioning it as a comprehensive cell and gene therapy platform provider with potential margin and revenue diversification benefits.
• Guidance Reflects Caution and Confidence: Conservative 2025 guidance acknowledges macro uncertainties but signals management’s confidence in commercial execution and pipeline maturation to drive sustainable growth.

Conclusion

MaxCyte’s fourth quarter and full-year 2024 results underscore a business successfully navigating milestone revenue volatility and macro challenges through core revenue growth and strategic expansion. The SecureDx acquisition enhances MaxCyte’s value proposition, while disciplined operations and a robust balance sheet position the company well for 2025. Investors should monitor milestone progress and macro trends as key drivers of future performance.

Industry Read-Through

MaxCyte’s results highlight broader industry dynamics in the cell and gene therapy space, where milestone-driven revenues introduce lumpiness and recurring consumable sales provide stability. The integration of safety profiling services like SecureDx reflects increasing industry emphasis on safety and regulatory compliance, signaling a trend towards comprehensive platform offerings. The cautious capital spending environment among biotech customers is a common theme, underscoring the importance of diversified revenue streams and operational discipline. Other platform providers may look to expand service capabilities and focus on consumable-driven models to mitigate revenue volatility and capture growing clinical pipelines.

MXCT Healthcare Biotechnology Cell Therapy Recurring Revenue Acquisition Milestone Revenue